Considering the loss of DTC dendritic structures and the cell adhesions on them (Fig
Bora E, McIntyre RS, Ozerdem A
The slow intravenous infusion protocols used in clinical trials minimized these effects, suggesting that rapid bolus administration (which is essentially what subcutaneous injection creates) may increase the likelihood of transient side effects
Consequently, the question arises as to whether these agents are superior to liraglutide in BAD treatment
However, this does not mean patients never experience this symptomrather, it reflects that dark urine typically results from secondary effects rather than direct drug action
To say that you need to try and fail before you can start a medication is losing time, particularly for our cardiac patients who have cardiovascular disease